HOME >> MEDICINE >> NEWS
9th European Congress on Lung Disease

The 9th annual meeting of the European Respiratory Society (ERS) will be held in Madrid, Spain, this fall. This is the leading gathering of respiratory specialists in Europe. Presentations will be given of the unpublished results of over 3000 studies covering the extremely broad-ranging field of respiratory and lung diseases.

Lung cancer, asthma, chronic bronchitis and sleep apnoea are just some of the topics that will be addressed at this annual Congress.

"It is one of the year's outstanding scientific events", says Nicols Gonzlez Mangado, the chairman of the congress. "This meeting will be a unique, historic occasion, as Spain will be welcoming over 10'000 of the world's leading specialists in respiratory pathology".

Over and above the 3000 advanced studies that have been selected for free communications (either oral presentations or posters), the program includes over 50 specialized symposia featuring the best experts, and covering a range from basic and applied research to still unpublished clinical trials.

"This meeting offers a very attractive combination for a wide audience of specialists, adds Manuel Cosio, the Vice-Chairman of the meeting. That is why the ERS has attracted more and more investigators from all over the world and why our annual meeting is really growing in importance. Madrid got a record number of submitted 3740 abstracts, out of which 3035 were accepted, Manuel Cosio is pleased to report.

One of the symposia, for instance, will be devoted to highly promising new approaches to the prevention of lung cancer. Very recent advances in this field have opened the way to pre-invasive cancer treatment, which stops the formation of cancer cells using an aerosol that will soon undergo human trials. Also in the field of lung cancer, the meeting will be told how it is becoming possible, using sophisticated medical imaging (computerized tomography) techniques, to diagnose the illness at a sufficiently early stage to apply therapy.
'"/>

Contact: Eric Schaerlig or Armelle Dulac
ERS99EK@cedos.int.ch
41-22-827-38-27
European Respiratory Society
7-Sep-1999


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: European Congress Lung Disease

(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: